Antitumorigenic evaluation of thalidomide alone and in combination with cisplatin in DBA2/J mice

Thalidomide's reported ability to inhibit angiogenesis has led to clinical trials determining its effectiveness in combating various types of cancer. This study explored thalidomide's antitumorigenic potential when administered alone and in combination with cisplatin to DBA2/J mice whose tumors were induced by murine erythroleukemic cells. Thalidomide treatment alone produced no significant inhibitory effect on tumor development and metastasis. Mice that received both drugs had significantly lower incidences of both primary and secondary tumors as compared to the untreated control group. Cisplatin, administered alone or in combination with thalidomide, led to a significant delay in tumor formation and a longer life span than was recorded in untreated mice. However, the combination treatment results were not significantly different from those of cisplatin treatment used as a single agent. In in vitro cell multiplication studies using murine erythroleukemic and murine endothelial cells, thalidomide failed to inhibit cell proliferation. However, cisplatin treatment with or without thalidomide, significantly inhibited the multiplication of both cell lines in a dose dependent manner. Thalidomide does not appear to be a beneficial adjuvant to cisplatin treatment.

Title	Antitumorigenic evaluation of thalidomide alone and in combination with cisplatin in DBA2/J mice
Creator	Ruddy, J. M. B.
Creator	Majumdar, Shyamal K.
Publisher	Journal of Biomedicine and Biotechnology
Academic Department	Biology
Division	Natural Sciences
Organization	Lafayette College
Date Issued	2002
Date Available	2015-06-05T20:30:47Z
Type	Article
Language	English
Bibliographic Citation	Ruddy, J. M. B. and S. K. Majumdar (2002) "Antitumorigenic evaluation of thalidomide alone and in combination with cisplatin in DBA2/J mice." Journal of Biomedicine and Biotechnology 2 (1): 7-13.
Standard Identifier	DOI 10.1155/S1110724302000359
Standard Identifier	Handle 10385/1996
Permalink	http://hdl.handle.net/10385/1996
Rights Statement	In Copyright
Rights Holders	Hindawi Publishing Corporation